| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Margaret Stanley | Q88958740 |
| P2860 | cites work | The papillomavirus life cycle | Q28238578 |
| Papillomaviruses and cancer: from basic studies to clinical application | Q29614745 | ||
| Classification of papillomaviruses | Q29618731 | ||
| Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine | Q31961522 | ||
| Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. | Q33803580 | ||
| Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes | Q33839638 | ||
| The serological response to papillomaviruses | Q33860420 | ||
| Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan | Q34004909 | ||
| Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses | Q34148415 | ||
| Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. | Q34410767 | ||
| Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only | Q34568949 | ||
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 | ||
| IMMUNIZATION OF RABBITS TO INFECTIOUS PAPILLOMATOSIS. | Q34659364 | ||
| Links between innate and adaptive immunity via type I interferon | Q34712647 | ||
| Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. | Q35840539 | ||
| Mechanisms of human papillomavirus-induced oncogenesis. | Q35915935 | ||
| Immune responses to human papillomavirus | Q36283939 | ||
| Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers | Q36524778 | ||
| Chapter 2: The burden of HPV-related cancers | Q36584354 | ||
| Chapter 13: Current findings from prophylactic HPV vaccine trials | Q36584357 | ||
| High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up | Q36612475 | ||
| Mechanisms used by human papillomaviruses to escape the host immune response. | Q36737715 | ||
| Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? | Q36851090 | ||
| Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. | Q37568227 | ||
| Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials | Q40207173 | ||
| Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions | Q42625439 | ||
| Immunological events in regressing genital warts | Q43760914 | ||
| Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice | Q44996013 | ||
| Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity | Q45403282 | ||
| Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine | Q45404033 | ||
| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
| Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection | Q45745673 | ||
| Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection | Q46215592 | ||
| Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes | Q48561611 | ||
| Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs | Q48561706 | ||
| The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. | Q50995710 | ||
| Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. | Q53342013 | ||
| Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 | Q60321491 | ||
| Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts | Q72351426 | ||
| Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus | Q73804558 | ||
| Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release | Q80088065 | ||
| Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta | Q81298773 | ||
| Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 | Q83925050 | ||
| P433 | issue | 2 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HPV vaccine | Q900189 |
| P304 | page(s) | S15-21 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Immunobiology of HPV and HPV vaccines | |
| P478 | volume | 109 |
| Q36106799 | A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization |
| Q36448778 | A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5 |
| Q34992751 | APOBEC3A functions as a restriction factor of human papillomavirus |
| Q59329445 | Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus |
| Q37472898 | An African perspective on mucosal immunity and HIV-1. |
| Q92867229 | An investigation into the role of chronic Schistosoma mansoni infection on Human Papillomavirus (HPV) vaccine induced protective responses |
| Q33873719 | Antibody responses against xenotropic murine leukemia virus-related virus envelope in a murine model |
| Q54421128 | Are women with lupus at higher risk of HPV infection? |
| Q90706200 | Association between interleukin-2, interleukin-10, secretory immunoglobulin A and immunoglobulin G expression in vaginal fluid and human papilloma virus outcome in patients with cervical lesions |
| Q34187046 | Association between toll-like receptor expression and human papillomavirus type 16 persistence |
| Q34410377 | Characterization and enzyme-conjugation of a specific anti-L1 nanobody |
| Q37845180 | Chlamydia trachomatis infection and human papillomavirus in women with cervical neoplasia in Pernambuco-Brazil. |
| Q37878482 | Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains |
| Q40238348 | Cohort Profile: African Collaborative Center for Microbiome and Genomics Research's (ACCME) Human Papillomavirus (HPV) and Cervical Cancer Study |
| Q84520481 | Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia |
| Q51007196 | Could the human papillomavirus vaccines drive virulence evolution? |
| Q37607686 | Dendritic cell targeting vaccine for HPV-associated cancer |
| Q37384735 | Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination |
| Q37172862 | Developmental regulation of hepatitis B virus biosynthesis by hepatocyte nuclear factor 4alpha |
| Q37318334 | Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women |
| Q56967486 | Emerging human papillomavirus vaccines |
| Q33547396 | Enhancing cellular cancer vaccines |
| Q37826158 | Eurogin 2010 roadmap on cervical cancer prevention |
| Q35901974 | Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine |
| Q35228757 | Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure |
| Q35757389 | Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine |
| Q52625020 | Extracellular conformational changes in the capsid of human papillomaviruses contribute to asynchronous uptake into host cells. |
| Q38647798 | Functional characterization of CD4 and CD8 T cell responses among human papillomavirus infected patients with ano-genital warts |
| Q35929062 | Functional flexibility of intestinal IgA - broadening the fine line |
| Q39178605 | Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran. |
| Q47578379 | Grand challenges in modulating the immune response with RNAi nanomedicines. |
| Q41934319 | HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers |
| Q37581762 | HPV as a model for the development of prophylactic and therapeutic cancer vaccines. |
| Q28652424 | HPV clearance and the neglected role of stochasticity |
| Q37145093 | HPV infection: immunological aspects and their utility in future therapy |
| Q34335370 | HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future |
| Q28088327 | Human Papillomavirus Infection, Infertility, and Assisted Reproductive Outcomes |
| Q36475069 | Human genomic diversity, viral genomics and proteomics, as exemplified by human papillomaviruses and H5N1 influenza viruses |
| Q47553973 | Human papilloma virus-specific T cells can be generated from naïve T cells for use as an immunotherapeutic strategy for immunocompromised patients. |
| Q36086249 | Human papillomavirus immunization is associated with increased expression of different innate immune regulatory receptors |
| Q34743370 | Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease |
| Q45158133 | Human papillomavirus type 16 E6 and NFX1-123 mislocalize immune signaling proteins and downregulate immune gene expression in keratinocytes |
| Q37345134 | Human papillomavirus vaccine and cervical cancer prevention |
| Q35541384 | Hypoxia inducible factor-1 alpha expression is increased in infected positive HPV16 DNA oral squamous cell carcinoma and positively associated with HPV16 E7 oncoprotein |
| Q37636476 | IPA Analysis of Cervicovaginal Fluid from Precancerous Women Points to the Presence of Biomarkers for the Precancerous State of Cervical Carcinoma |
| Q35532771 | Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody |
| Q34172304 | Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid |
| Q35647677 | Immune Dysregulation in Patients Persistently Infected with Human Papillomaviruses 6 and 11. |
| Q40060642 | Immune evasion mechanisms of human papillomavirus: An update |
| Q39982103 | Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. |
| Q47549756 | Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development |
| Q42280340 | Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose |
| Q36305499 | Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials |
| Q36100837 | Immunology and Immunotherapy of Head and Neck Cancer |
| Q26744094 | Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research |
| Q60912649 | Importance of High-Risk Human Papillomavirus Infection Detection in Female Renal Transplant Recipients in the First Year after Transplantation |
| Q92854325 | Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform |
| Q33865960 | Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection |
| Q39744237 | Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes |
| Q53309083 | Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1. |
| Q28274001 | Introducing human papillomavirus vaccines into the health system in South Africa |
| Q33468660 | Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. |
| Q34546550 | Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study |
| Q57055717 | Osmolytes in vaccine production, flocculation and storage: a critical review |
| Q35072682 | Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis |
| Q34690139 | Persistence of human papillomavirus infection: keys to malignant progression |
| Q35577825 | Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years |
| Q33783092 | Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia |
| Q44209664 | Prevalence and genotypes' distribution of human papillomavirus in invasive cervical cancer in Saudi Arabia |
| Q35164233 | Prevalence of human papillomavirus genotypes and associated cervical squamous intraepithelial lesions in HIV-infected women in Botswana |
| Q34069384 | Prevalence of human papillomavirus infection and phylogenetic analysis of HPV-16 E6 variants among infected women from Northern Brazil. |
| Q47141407 | Prevalence of oncogenic human papillomavirus genotypes in patients diagnosed with anogenital malignancies in Botswana |
| Q36174293 | Prevalence of the NKG2D Thr72Ala polymorphism in patients with cervical carcinoma. |
| Q33759930 | Prospects for prevention of HPV-driven oropharynx cancer |
| Q38566309 | Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art |
| Q50238227 | Regulation of the human papillomavirus type 16 late promoter by E7 and the cell cycle |
| Q37225996 | Retrieval of HPV oncogenes E6 and E7 mRNA from cervical specimens using a manual open technology protocol |
| Q39062769 | Screening for cervical carcinoma in HIV-infected women: Analysis of main risk factors for cervical cytologic abnormalities. |
| Q90147842 | Selection of adjuvants for vaccines targeting specific pathogens |
| Q85238283 | Serological markers for papillomavirus infection and skin tumour development in the rodent model Mastomys coucha |
| Q55238817 | Sinecatechins Ointment, 15% for the Treatment of External Genital and Perianal Warts: Proceedings of an Expert Panel Roundtable Meeting. |
| Q91775763 | Suppression of Stromal Interferon Signaling by Human Papillomavirus 16 |
| Q38851114 | Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies |
| Q58572928 | Th17 response in patients with cervical cancer |
| Q90055122 | The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease |
| Q38839706 | The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus |
| Q38041983 | Understanding and learning from the success of prophylactic human papillomavirus vaccines. |
| Q37779817 | Vaccines based on whole recombinant Saccharomyces cerevisiae cells |
Search more.